A detailed history of Pathstone Family Office, LLC transactions in Bio N Tech Se stock. As of the latest transaction made, Pathstone Family Office, LLC holds 1,997 shares of BNTX stock, worth $159,480. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,997
Holding current value
$159,480
% of portfolio
0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 08, 2023

BUY
$98.5 - $125.08 $196,704 - $249,784
1,997 New
1,997 $216,000
Q1 2023

May 15, 2023

SELL
$122.57 - $153.67 $45,596 - $57,165
-372 Reduced 16.87%
1,833 $228,000
Q4 2022

Oct 23, 2023

BUY
$118.43 - $186.05 $12,198 - $19,163
103 Added 4.9%
2,205 $331,000
Q4 2022

Feb 13, 2023

BUY
$118.43 - $186.05 $12,198 - $19,163
103 Added 4.9%
2,205 $331,000
Q3 2022

Oct 23, 2023

BUY
$127.65 - $183.11 $68,803 - $98,696
539 Added 34.48%
2,102 $283,000
Q3 2022

Nov 14, 2022

BUY
$127.65 - $183.11 $68,803 - $98,696
539 Added 34.48%
2,102 $284,000
Q2 2022

Oct 23, 2023

BUY
$123.25 - $186.24 $192,639 - $291,093
1,563 New
1,563 $233,000
Q2 2022

Aug 15, 2022

SELL
$123.25 - $186.24 $47,574 - $71,888
-386 Reduced 19.81%
1,563 $233,000
Q1 2022

May 16, 2022

BUY
$126.25 - $231.85 $35,350 - $64,918
280 Added 16.78%
1,949 $332,000
Q4 2021

Feb 14, 2022

BUY
$216.64 - $362.52 $56,109 - $93,892
259 Added 18.37%
1,669 $430,000
Q3 2021

Nov 16, 2021

BUY
$205.93 - $447.23 $3,706 - $8,050
18 Added 1.29%
1,410 $385,000
Q2 2021

Aug 31, 2021

BUY
$113.32 - $241.49 $157,741 - $336,154
1,392 New
1,392 $312,000
Q1 2021

May 14, 2021

SELL
$85.73 - $119.5 $17,146 - $23,900
-200 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$72.71 - $129.54 $7,270 - $12,954
-100 Reduced 33.33%
200 $16,000
Q3 2020

Nov 12, 2020

BUY
$57.81 - $104.17 $5,781 - $10,417
100 Added 50.0%
300 $21,000
Q2 2020

Aug 14, 2020

BUY
$38.58 - $66.74 $7,716 - $13,347
200 New
200 $13,000

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $19.4B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Pathstone Family Office, LLC Portfolio

Follow Pathstone Family Office, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Family Office, LLC with notifications on news.